ATNM - צמיחת הכנסות משנה לשנה ב-12 החודשים האחרונים actiniumpharma.com

Actinium Pharmaceuticals (ATNM) leads the development of advanced radiopharmaceuticals for the therapy of hematological tumors, actively advancing the Iomab-B project. The company's TTM revenue growth rate visualizes this progress, where the 38843.70 mark reflects the current state. A unique isotope delivery method will ensure complete pricing power, although the business currently relies heavily on external contractors for stable drug production.
Actinium Pharma (ATNM) - פילוחי מדדים ודוחות פיננסיים

Investors are evaluating Actinium Pharmaceuticals (ATNM) through the lens of its unique positioning in radiopharmaceuticals. This metric measures the daily change in annual revenue over a rolling 12-month period, revealing the actual vector of operational growth. Analyzing the year-over-year sales growth percentage for TTM allows for tracking revenue acceleration prior to the market launch of Iomab-B. Complex isotope logistics minimize competition, making this indicator a key marker of commercial scaling. A stable trend will confirm the fundamental resilience of the business.